[go: up one dir, main page]

WO1998013501A3 - Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales - Google Patents

Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales Download PDF

Info

Publication number
WO1998013501A3
WO1998013501A3 PCT/US1997/016718 US9716718W WO9813501A3 WO 1998013501 A3 WO1998013501 A3 WO 1998013501A3 US 9716718 W US9716718 W US 9716718W WO 9813501 A3 WO9813501 A3 WO 9813501A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
promoter region
polymerase gene
attenuation
genomic promoter
Prior art date
Application number
PCT/US1997/016718
Other languages
English (en)
Other versions
WO1998013501A2 (fr
Inventor
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Original Assignee
American Cyanamid Co
Us Health
Mohinderjit S Sidhu
Stephen A Udem
Joanne M Tatem
Brian R Murphy
Valerie B Randolph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Us Health, Mohinderjit S Sidhu, Stephen A Udem, Joanne M Tatem, Brian R Murphy, Valerie B Randolph filed Critical American Cyanamid Co
Priority to EP97942613A priority Critical patent/EP0932684A2/fr
Priority to BR9712138-0A priority patent/BR9712138A/pt
Priority to AU44278/97A priority patent/AU4427897A/en
Priority to CA002265554A priority patent/CA2265554A1/fr
Priority to JP10515749A priority patent/JP2000517194A/ja
Publication of WO1998013501A2 publication Critical patent/WO1998013501A2/fr
Publication of WO1998013501A3 publication Critical patent/WO1998013501A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention concerne des virus d'ARN de l'ordre des Mononegavirales qui sont isolés, produits par recombinaison, atténués, non segmentés, à sens négatif et monocaténaires, et qui présentent au moins une mutation d'atténuation dans la région promotrice 3' du génome et au moins une mutation d'atténuation dans le gène polymérase de l'ARN. On formule des vaccins avec ces virus et un support physiologiquement acceptable. Ces vaccins permettent d'immuniser un individu par induction d'une protection contre un virus monocaténaire, non segmenté et à sens négatif de l'ordre des Mononegavirales.
PCT/US1997/016718 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales WO1998013501A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97942613A EP0932684A2 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
BR9712138-0A BR9712138A (pt) 1996-09-27 1997-09-19 Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
AU44278/97A AU4427897A (en) 1996-09-27 1997-09-19 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
CA002265554A CA2265554A1 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
JP10515749A JP2000517194A (ja) 1996-09-27 1997-09-19 モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2682396P 1996-09-27 1996-09-27
US60/026,823 1996-09-27

Publications (2)

Publication Number Publication Date
WO1998013501A2 WO1998013501A2 (fr) 1998-04-02
WO1998013501A3 true WO1998013501A3 (fr) 1998-08-13

Family

ID=21833976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016718 WO1998013501A2 (fr) 1996-09-27 1997-09-19 Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales

Country Status (8)

Country Link
EP (1) EP0932684A2 (fr)
JP (1) JP2000517194A (fr)
KR (1) KR20000048628A (fr)
CN (1) CN1232504A (fr)
AU (1) AU4427897A (fr)
BR (1) BR9712138A (fr)
CA (1) CA2265554A1 (fr)
WO (1) WO1998013501A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
AU9389998A (en) * 1997-09-19 1999-04-12 American Cyanamid Company Attenuated respiratory syncytial viruses
AU767193B2 (en) * 1998-03-26 2003-11-06 Wyeth Holdings Corporation Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B
AU761234B2 (en) 1998-06-03 2003-05-29 Wyeth Holdings Corporation Novel methods for rescue of RNA viruses
MXPA00012402A (es) 1998-06-12 2003-07-14 Sinai School Medicine Metodos y substratos deficientes de interferon, novedosos, para la propagacion de virus.
US6468544B1 (en) 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
PT1292615E (pt) * 2000-06-23 2007-01-31 Wyeth Corp Proteínas v modificadas d morbillivirus
US7361496B1 (en) 2000-08-02 2008-04-22 Wyeth Rescue of mumps virus from cDNA
ES2393468T3 (es) 2001-01-19 2012-12-21 Vironovative B.V. Un virus que provoca enfermedad de las vías respiratorias en mamíferos susceptibles
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
CA2743750A1 (fr) 2002-02-21 2003-09-04 Medimmune, Llc Systemes d'expression de virus recombinant parainfluenza et vaccins comprenant des antigenes heterologues derives d'un virus syncytial respiratoire
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
WO2003091401A2 (fr) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Systeme multiplasmide de production de virus influenza
DE60233038D1 (de) * 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
EP1375670B1 (fr) 2002-06-20 2013-06-12 Institut Pasteur Virus de la rougeole recombinants exprimant des épitopes d' antigènes de virus à ARN et utilisation des virus recombinants pour la préparation de vaccins
CA2432738A1 (fr) * 2003-02-26 2004-08-26 Philippe Despres Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques
WO2004087062A2 (fr) * 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
EP1623006A4 (fr) 2003-04-25 2009-10-28 Medimmune Vaccines Inc Souches de metapneumovirus et leur utilisation dans des preparations de vaccin et en tant que vecteurs pour l'expression de sequences d'antigenes et procedes pour propager un virus
EP1633312A4 (fr) 2003-06-16 2012-09-26 Medimmune Llc Hemagglutinine du virus de la grippe et variantes de la neuraminidase
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
US7527800B2 (en) 2004-05-25 2009-05-05 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CA2610632C (fr) 2004-06-01 2022-10-04 Mount Sinai School Of Medicine Of New York University Virus de la grippe porcine genetiquement modifie et ses applications
WO2006088481A2 (fr) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Virus de la grippe equine genetiquement modifie et utilisations associees
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
AU2006262381A1 (en) 2005-06-21 2007-01-04 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CN101365479B (zh) 2005-12-02 2013-06-26 纽约大学西奈山医学院 呈现非天然表面蛋白的嵌合病毒及其应用
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン，エルエルシー イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
EP2056872A4 (fr) 2006-08-09 2016-12-21 Medimmune Llc Variants d'hémagglutinine et de neuraminidase de la grippe
CA2673535A1 (fr) 2006-12-22 2008-11-20 The Penn State Research Foundation Polymerases modifiees et virus attenues et leurs procedes d'utilisation
EP2069484B1 (fr) 2007-06-18 2014-08-13 MedImmune, LLC Virus B de la grippe présentant des modifications du polypeptide de l'hémagglutinine
MX2011000437A (es) 2008-07-11 2012-03-07 Medimmune Llc Variantes de hemaglutinina y neuramnidasa de influenza.
NZ592368A (en) 2008-11-05 2013-11-29 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
EP2396033B1 (fr) 2009-02-12 2016-09-28 MedImmune, LLC Hémagglutinine du virus de la grippe et variants de la neuraminidase
CA2787099A1 (fr) 2009-03-30 2010-10-14 Anice C. Lowen Polypeptides d'hemagglutinine du virus de l'influenza renfermant des domaines souches, vaccins et utilisations associees
WO2011014504A1 (fr) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Vecteurs du virus de la grippe recombiné et utilisations de ceux-ci
WO2011014645A1 (fr) 2009-07-30 2011-02-03 Mount Sinai School Of Medicine Of New York University Virus de la grippe et leurs utilisations
EP2552479A4 (fr) 2010-03-30 2015-03-04 Sinai School Medicine Vaccins contre le virus de la grippe et utilisations associées
EP2420242A1 (fr) 2010-08-20 2012-02-22 Lauer, Ulrich M. Virus de la rougeole oncolytique
JP6087908B2 (ja) * 2011-06-08 2017-03-08 ジョシ ヴィシュワスＪＯＳＨＩ Ｖｉｓｈｗａｓ 組換えタンパク質および組換えウイルスを作製するための単純な２プラスミド哺乳動物発現系
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
JP6498439B2 (ja) 2011-09-20 2019-04-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
EP2895191B1 (fr) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Protéine brachyury, vecteurs adénoviraux codant pour la protéine brachyury, et leur utilisation
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105188746B (zh) 2013-03-14 2020-03-17 西奈山伊坎医学院 新城疫病毒及其用途
KR102407019B1 (ko) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
CN116196403A (zh) 2015-08-03 2023-06-02 美国卫生和人力服务部 Brachyury缺失突变体、编码该缺失突变体的非酵母载体及其用途
WO2017031401A2 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus ns1 tronqué pour le développement de vaccins contre la grippe canine
WO2017031408A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus à cycle unique pour le développement de vaccins contre la grippe canine
WO2017031404A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine
CN109414488A (zh) 2016-06-03 2019-03-01 罗切斯特大学 马流感病毒减毒活疫苗
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
CA3058652A1 (fr) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2019168911A1 (fr) 2018-02-27 2019-09-06 University Of Rochester Vaccin vivant atténué multivalent contre la grippe pour la prévention et le contrôle du virus de la grippe équine (eiv) chez les chevaux
EP3810634A4 (fr) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Polypeptides d'hémagglutinines du virus de la grippe en mosaïque et leurs utilisations
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
EP3930749A1 (fr) 2019-02-27 2022-01-05 University of Rochester Vaccin multivalent à virus vivants atténués contre la grippe pour la prévention et le contrôle du virus de la grippe équine (eiv) chez les chevaux
US11103576B1 (en) 2020-06-15 2021-08-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Measles virus vaccine expressing SARS-COV-2 protein(s)
WO2025019631A1 (fr) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Compositions immunogènes contenant un virus de la grippe a inactivé et un adjuvant oligonucléotidique cpg et leurs utilisations
WO2025080985A1 (fr) 2023-10-13 2025-04-17 Flagship Pioneering Innovations V, Inc. Distribution d'anellovecteur spécifique à un tissu
WO2025160409A1 (fr) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Vecteurs viraux pour moduler la fonction vegf

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (fr) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN ADNc correspondant au génome des virus à ARN "brin-négatifs" et procédé pour la production de virus à ARN "brin-négatifs" infectieux
EP0540135A2 (fr) * 1991-10-14 1993-05-05 The Kitasato Institute Souche attenuée vaccinale du virus de la rougeole, contenant une séquence nucléotidique spécifique et procédé pour son identification absolue
EP0567100A1 (fr) * 1992-04-21 1993-10-27 American Cyanamid Company Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et méthodes d'utilisation
WO1993021306A1 (fr) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Virus attenues par genie genetique
WO1993021310A1 (fr) * 1992-04-21 1993-10-28 American Home Products Corporation Compositions de vaccins a base de virus respiratoire syncytial attenue
EP0702085A1 (fr) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Virus ARN récombinant, infectieux, non-segmenté, brin-négatif

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (fr) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN ADNc correspondant au génome des virus à ARN "brin-négatifs" et procédé pour la production de virus à ARN "brin-négatifs" infectieux
EP0540135A2 (fr) * 1991-10-14 1993-05-05 The Kitasato Institute Souche attenuée vaccinale du virus de la rougeole, contenant une séquence nucléotidique spécifique et procédé pour son identification absolue
WO1993021306A1 (fr) * 1992-04-14 1993-10-28 The Mount Sinai School Of Medicine Of The City University Of New York Virus attenues par genie genetique
EP0567100A1 (fr) * 1992-04-21 1993-10-27 American Cyanamid Company Virus syncytial respiratoire (RSV) mutant, vaccins le contenant et méthodes d'utilisation
WO1993021310A1 (fr) * 1992-04-21 1993-10-28 American Home Products Corporation Compositions de vaccins a base de virus respiratoire syncytial attenue
EP0702085A1 (fr) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Virus ARN récombinant, infectieux, non-segmenté, brin-négatif

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLLINS P.L. ET AL.: "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11563 - 11567, XP002066592 *
CROWE J.E. ET AL.: "Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.", VIRUS GENES, vol. 13, no. 3, February 1996 (1996-02-01), pages 269 - 273, XP002066591 *
MORI T. ET AL.: "Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus.", VIRUS GENES, vol. 7, no. 1, 1993, pages 67 - 81, XP002051752 *
RADECKE F. ET AL.: "RESCUE OF MEASLES VIRUSES FROM CLONED DNA", EMBO JOURNAL, vol. 14, no. 23, 1 December 1995 (1995-12-01), pages 5773 - 5784, XP002022952 *
STOKES A. ET AL.: "The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses(cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3).", VIRUS RESEARCH, vol. 30, 1993, pages 43 - 52, XP002051711 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Also Published As

Publication number Publication date
CA2265554A1 (fr) 1998-04-02
CN1232504A (zh) 1999-10-20
BR9712138A (pt) 2000-01-18
JP2000517194A (ja) 2000-12-26
AU4427897A (en) 1998-04-17
EP0932684A2 (fr) 1999-08-04
WO1998013501A2 (fr) 1998-04-02
KR20000048628A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
WO1998013501A3 (fr) Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
CA2011878A1 (fr) Regions immunogenes sur la proteine e7 du papillomavirus humain de type 16
EP1128832A4 (fr) Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees
WO2004014314A3 (fr) Procedes et compositions concernant les poxvirus et le cancer
WO1995032298A3 (fr) Vecteurs surs pour therapie genique
WO2001068103A3 (fr) Methode pouvant ameliorer les symptomes d'une infection herpetique au moyen de sequences polynucleotidiques immunomodulatrices
FI971272A7 (fi) Heikennetty rokotus- ja geenisiirtovirus, menetelmä viruksen valmista miseksi ja virusta sisältävä farmaseuttinen koostumus
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2186044A1 (fr) Nouveaux virus mutes, composes antiviraux et nouveaux procedes de production de vaccins
GB9306731D0 (en) Vaccines
ATE157370T1 (de) Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
CA2329510A1 (fr) Sequences de type promoteur exprimees dans les antheres et les pollens
WO2001077358A3 (fr) Virus de l'herpes destines a l'immunomodulation
WO2000034445A3 (fr) Vaccin vivant attenue de l'encephalomyelite equine du venezuela
AU4425397A (en) Antisense gene therapy for rna viruses
WO1999049017A3 (fr) Mutations responsables de l'attenuation du virus de la rougeole ou du virus respiratoire syncytial humain du sous-groupe b
CA2066998A1 (fr) Virus de la varicella-zona recombinant et procede de construction
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97198321.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997942613

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2265554

Country of ref document: CA

Ref document number: 2265554

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09269367

Country of ref document: US

ENP Entry into the national phase

Ref document number: 1998 515749

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997002569

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997942613

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997002569

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997942613

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997002569

Country of ref document: KR